HAVCR2 and glioblastoma: LAG-3 (lymphocyte activation gene 3), TIM-3 (T-cell immunoglobulin and mucin 3), TIGIT (T-cell immunoreceptor with Ig and ITIM domains), and IDO1 are the new targets being investigation in GBM [158].